[
    {
        "role": "user",
        "content": "what%20is%20the%20name%20of%20the%20drug%20used%20for%20non%2024%20and%20people%20who%20are%20blind%20with%20no%20light%20perception"
    },
    {
        "role": "assistant",
        "content": "The drug used to treat Non-24-Hour Sleep-Wake Disorder (Non-24) in people who are totally blind (with **no light perception**) is called **tasimelteon**, marketed under the brand name **Hetlioz**. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))\n\nHere\u2019s a bit more detail:\n\n- Tasimelteon is a **melatonin receptor agonist**\u2014it specifically acts on the MT\u2081 and MT\u2082 receptors in the brain, which helps align (or *entrain*) the internal body clock to a 24-hour cycle. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Tasimelteon?utm_source=openai))  \n- It was FDA-approved in **January 2014** for Non-24 in blind individuals with no light perception. ([medscape.com](https://www.medscape.com/viewarticle/820047?utm_source=openai))  \n- In clinical trials (called SET and RESET), totally blind individuals taking 20 mg of tasimelteon nightly saw significant improvements compared to placebo\u2014better nighttime sleep, reduced daytime sleep, and successful entrainment of their circadian rhythms. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=26466871&utm_source=openai))  \n\nIf you want information about side effects, how it\u2019s prescribed, or alternatives, I can pull that up too."
    },
    {
        "role": "user",
        "content": "yes"
    },
    {
        "role": "assistant",
        "content": "Here's a detailed breakdown of the side effects, dosage, warnings, and alternatives for **tasimelteon (Hetlioz)**\u2014the FDA-approved drug for Non-24-Hour Sleep-Wake Disorder in totally blind individuals with no light perception. These are based on the most recent and reliable sources.  \n\n---\n\n## Dosage & Administration\n\n- The standard dose for adults with Non-24 is **20 mg taken orally once daily** at the same time each night, *one hour before the desired bedtime*, on an empty stomach. ([medicine.com](https://www.medicine.com/drug/tasimelteon/hcp?utm_source=openai))  \n- Take the capsule whole; do *not* open, crush, or chew it. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n- After taking the dose, avoid doing anything but preparing for sleep (e.g., reading or hygiene); this is because tasimelteon causes drowsiness. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n- Note: It may take **weeks or months** of nightly use before full benefits are seen due to individual variation in circadian rhythms. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n\n---\n\n## Side Effects & Safety Information\n\n### Common Side Effects\n\nBased on clinical studies (particularly the SET and RESET trials) involving totally blind individuals:\n\n- **Headache** (~17% of users vs. ~7% with placebo) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27003694/?utm_source=openai))  \n- **Nightmares or abnormal dreams** (~10%) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27003694/?utm_source=openai))  \n- **Elevated liver enzymes** (~10% vs. ~5% placebo) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- **Upper respiratory infections**, urinary tract infections ([medicine.com](https://www.medicine.com/drug/tasimelteon/hcp?utm_source=openai))  \n\n### Less Common / Serious Issues\n\n- Drowsiness or reduced alertness, particularly after taking the medication. Don\u2019t drive or operate machinery until you know how it affects you. ([mayoclinic.org](https://www.mayoclinic.org/drugs-supplements/tasimelteon-oral-route/description/drg-20095155?utm_source=openai))  \n- Potential interactions in **hepatic impairment** (severe cases not studied) and **renal impairment**. In mild to moderate liver issues, dosage adjustment isn\u2019t usually needed. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n- Drug-drug interactions: Tasimelteon is primarily metabolized by CYP1A2 and CYP3A4. Strong inhibitors of these enzymes can increase drug levels; strong inducers may reduce effectiveness. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK548636/?utm_source=openai))  \n\n---\n\n## Warnings & Precautions\n\n- Do *not* abruptly stop taking the medication without discussing with your healthcare provider; it\u2019s intended to be taken continuously to keep your circadian rhythms synced. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Avoid or limit **alcohol** while taking tasimelteon, as it can worsen sedative effects. ([medicine.com](https://www.medicine.com/drug/tasimelteon/hcp?utm_source=openai))  \n- Smoking can reduce drug effectiveness because it induces CYP1A2, lowering plasma concentrations of tasimelteon. ([medicine.com](https://www.medicine.com/drug/tasimelteon/hcp?utm_source=openai))  \n- Not studied in severe hepatic impairment or in many pediatric patients under 16 for Non-24. Use with caution in elderly. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n\n---\n\n## Alternatives & Comparisons\n\n- **Melatonin**: Low-dose melatonin has been used off-label for Non-24, particularly in blind individuals. It can entrain circadian rhythms if taken at appropriate times (often several hours before desired bedtime). However, it's *not* FDA-approved for this condition. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- There are **no head-to-head clinical trials** comparing tasimelteon and melatonin for Non-24, so it\u2019s not proven one is superior in all respects. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- For some patients, melatonin is chosen over tasimelteon due to **lower cost**, greater accessibility, or personal preference\u2014but effectiveness can vary. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n\n---\n\nIf you like, I can also pull up typical costs, insurance coverage issues, or more detailed comparisons for specific cases."
    },
    {
        "role": "user",
        "content": "if%20one%20wants%20to%20use%20melatonin%20instead%2C%20what%20dosage%2C%20type%20of%20melatonin%20is%20used%2C%20etc."
    },
    {
        "role": "assistant",
        "content": "Here\u2019s what medical research and clinical experience say about using **melatonin** for Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals with **no light perception**. This covers dosing amounts, timing (including circadian phase), formulation types, and what to expect. Always consult a sleep specialist or physician before starting\u2014this area has nuance and what works for one person may not for another.\n\n---\n\n## Key principles\n\n- Since people with no light perception can\u2019t use light to synchronize (\u201centrain\u201d) their internal body clock, melatonin (or its agonists) is the main option to shift the internal circadian rhythm. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Timing is *crucial*. When melatonin is taken relative to an individual\u2019s internal circadian phase determines whether it advances (shifts earlier) or delays the rhythm. Taking it at the \u201cwrong\u201d time can worsen Non-24. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n\n---\n\n## Dosage\n\nHere are dosage ranges shown to have worked in studies:\n\n| Dose | Details / Study Findings |\n|---|---|\n| **0.5 mg once daily** | In a study of totally blind people (no light perception), 0.5 mg given nightly (~21:00) led to successful entrainment in *most* subjects over several weeks. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=14582858&utm_source=openai)) |\n| **5 mg once daily** | Some trials used immediate-release 5 mg doses; these helped some individuals entrain but responses varied. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai)) |\n| **10 mg initially** | In one crossover study, blind subjects took **10 mg** melatonin \u201cone hour before preferred bedtime\u201d daily for 3\u20139 weeks; most were entrained. Then dose was eventually tapered down to 0.5 mg, with entrainment maintained. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/publications/98797-entrainment-of-free-running-circadian-rhythms-by-melatonin-in-blind-people?utm_source=openai)) |\n\n---\n\n## Formulation Types\n\n- **Immediate-release (IR)** melatonin is most commonly used\u2014especially for phase shifting in Non-24 (to cause a sharp melatonin spike). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- **Prolonged-release (PR; also called extended release)** forms have been tested; e.g., **Circadin\u00ae 2 mg PR** nightly for 6 weeks improved total night sleep and fewer naps in totally blind people, though study sizes were small and effects modest. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4319556/?utm_source=openai))  \n\n---\n\n## Timing Relative to Circadian Phase\n\n- For those whose natural circadian period (tau) is **longer than 24 hours** (a common case in totally blind people), melatonin should be given roughly **6 hours before the *desired* bedtime**. This timing taps into the phase-advance portion of the melatonin phase response curve (PRC). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- In some studies, melatonin was administered at the individual's *wake time*, particularly for those whose tau is shorter than 24 or other special cases, though this is less common. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- Studies often fix a desired sleep schedule in advance \u2014 so you decide what time you *want* to go to sleep and wake up, then time your melatonin relative to that. Regularity (same time every night) is important. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n\n---\n\n## Putting It All Together: Sample Protocols\n\nHere are examples of what protocols have looked like in the research:\n\n- **Low-dose IR protocol**: 0.5 mg immediate-release melatonin taken ~6 hours before desired bedtime, every night; over several weeks resulted in entrainment in many study participants. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- **Initial high-dose then taper**: Start with 10 mg one hour before preferred bedtime until entrainment is achieved (3\u20139 weeks), then reduce gradually to a low maintenance dose such as 0.5 mg. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/publications/98797-entrainment-of-free-running-circadian-rhythms-by-melatonin-in-blind-people?utm_source=openai))  \n- **2 mg prolonged-release nightly**: Circadin\u00ae (PR melatonin) 2 mg taken each night for 6 weeks showed improvement in night sleep and fewer daytime naps in totally blind individuals, though entrainment wasn\u2019t as strong/mixed. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4319556/?utm_source=openai))  \n\n---\n\n## Side Effects / Risks with Melatonin\n\nCompared to prescription medications, melatonin is relatively safe, but side effects and risks exist:\n\n- Common mild side effects: **drowsiness**, daytime sleepiness or lingering drowsiness, headache, possibly vivid dreams or changes in mood. ([sleepfoundation.org](https://www.sleepfoundation.org/non-24-sleep-wake-disorder/treatment-care?utm_source=openai))  \n- May affect **blood pressure**, **glucose tolerance**, or mood\u2014monitor carefuly, especially if you have underlying health issues. ([sleepfoundation.org](https://www.sleepfoundation.org/non-24-sleep-wake-disorder/treatment-care?utm_source=openai))  \n- Melatonin supplements vary in quality and purity\u2014they are *not* regulated as strictly as prescription drugs in many countries (including the U.S.). Dose amounts printed on labels may be inaccurate. ([sleepfoundation.org](https://www.sleepfoundation.org/non-24-sleep-wake-disorder/treatment-care?utm_source=openai))  \n\n---\n\n## What to Expect / Practical Advice\n\n- Won\u2019t usually work overnight\u2014entrainment often takes **weeks**, sometimes a couple months of consistently timed dosing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Regular sleep\u2013wake schedule (same time going to bed and waking up each day), consistent routines (meals, activity), and minimizing factors that affect the circadian clock (like caffeine late in the day, irregular eating, etc.) help a lot. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n\n- After entrainment, lower maintenance doses may suffice\u2014but careful monitoring to ensure entrainment remains is important. Study showing tapering from 10 mg to ~0.5 mg maintained entrainment for months. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/publications/98797-entrainment-of-free-running-circadian-rhythms-by-melatonin-in-blind-people?utm_source=openai))  \n\n---\n\nIf you like, I can outline a personalized melatonin plan based on your schedule (desired sleep time, waking time, etc.), so you can see how this applies in *your* case."
    },
    {
        "role": "user",
        "content": "how%20is%20the%20different%20effectiveness%20between%20non%2024%20and%20melatonin"
    },
    {
        "role": "assistant",
        "content": "Here\u2019s a comparison of effectiveness between **tasimelteon** (an FDA-approved melatonin receptor agonist) and **melatonin supplements or formulations** for treating Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals (no light perception). Most of what we know comes from separate studies; there are *no* strictly head-to-head clinical trials between the two. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))\n\n---\n\n## What the Evidence Says: Entraining Rates & Success\n\n### Tasimelteon\n\n- In SET and RESET trials (randomized, double-blind, placebo-controlled) involving totally blind adults, *20 mg tasimelteon nightly 1 hour before target bedtime* led to **entrainment** of circadian rhythms (assessed via urinary aMT6s and cortisol) in about **20\u201328%** of subjects at month 1 (SET). Over longer timepoints, some analyses showed that **55\u201375%** of participants\u2014under more sensitive/enhanced monitoring\u2014showed entrainment after several weeks. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai))  \n- Once entrained, continued tasimelteon treatment maintained entrainment in **90%** of participants in the RESET trial, compared to a much lower maintenance (around 20%) if switched to placebo. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai))  \n\n### Melatonin (Various Types)\n\n- Some small crossover studies using **5\u201310 mg immediate-release melatonin** nightly showed success in entrainment in *most* participants (e.g., 6 out of 7 totally blind people in one study) after several weeks of consistent use. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Lower doses like **0.5 mg** nightly have also achieved entrainment in some people\u2014though more slowly and not universally. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Prolonged-release (extended-release) melatonin, such as Circadin 2 mg nightly, has shown improvements in sleep and daytime alertness, but less data exists for strong entrainment compared to immediate-release formulations. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n\n---\n\n## Direct Comparisons & What We Do *Not* Know\n\n- There are **no clinical trials directly comparing** tasimelteon vs melatonin for Non-24 in totally blind individuals. In other words, we don't have rigorous data showing one is definitively superior under all conditions. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n- Current reviews note that **rates of entrainment are \u201ccomparable\u201d** across published studies\u2014though methodologies differ, sample sizes are small for melatonin, and study designs (duration, measurement markers, daily routines) vary. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai))  \n\n---\n\n## Overall Strength & Weakness Profiles\n\n| Feature | Tasimelteon | Melatonin (IR/PR) |\n|--------|-------------|---------------------|\n| Regulatory approval | FDA/EMA-approved specifically for Non-24 in totally blind people with no light perception. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9810491/?utm_source=openai)) | Used off-label; not formally approved for Non-24 in many places. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28229310/?utm_source=openai)) |\n| Predictability / consistency | More predictable in formal trials; standardized dosing and timing; well-measured entrainment and maintenance. | Effects are more variable; depends heavily on timing, dose, adherence; smaller trials; some people respond better than others. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai)) |\n| Time to effect | In some cases, ~1-4 weeks for initial entrainment; better maintenance long term. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai)) | Some rapid responders (within 3-9 weeks with higher doses); others take longer; low doses slower. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai)) |\n| Maintenance of effect | High once entrained, per RESET (\u224890%) as long as treatment is continued. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai)) | Maintenance more fragile; when melatonin is stopped or not taken strictly, entrainment often lost. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai)) |\n| Cost / access / quality | More expensive; prescription required; standardized pharmaceutical agent. | More affordable; widely available; but concerns about dose precision, purity of supplements. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai)) |\n\n---\n\n## Bottom Line\n\n- **Tasimelteon** gives more consistent, predictable results, especially for maintaining entrainment over time, with methods rigorously studied. For individuals who *can reliably adhere* to timing and whose circadian period (tau) is well understood, it is often the \u201csafer bet\u201d\u2014especially when insurance and access permit.\n\n- **Melatonin** can\u2014*and does*\u2014work well in many cases, especially when properly timed, using immediate-release formulations and with consistent dosing. However, effectiveness is more variable, sometimes slower, and entrainment maintenance may be less reliable unless the regimen is strictly followed.\n\n---\n\nIf you tell me your circadian period (if known), what your typical sleep/wake times are, and whether strict scheduling and routine are possible for you, I can help estimate which might be more likely to work *in your case*."
    }
]